• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Recent Advances in the Application of (4-Bromo-3-methylphenyl)hydrazine (CAS: 90084-70-1) in Chemical Biology and Pharmaceutical Research

The compound (4-Bromo-3-methylphenyl)hydrazine (CAS: 90084-70-1) has recently gained significant attention in chemical biology and pharmaceutical research due to its versatile applications as a key synthetic intermediate and its potential biological activities. This research brief synthesizes the latest findings regarding this important chemical entity, with particular focus on its synthetic utility, mechanism of action, and emerging therapeutic applications.

Recent synthetic chemistry studies have demonstrated the effectiveness of (4-Bromo-3-methylphenyl)hydrazine as a building block for the preparation of various heterocyclic compounds. A 2023 study published in the Journal of Medicinal Chemistry reported its use in the synthesis of novel indazole derivatives with potent kinase inhibitory activity. The bromo and hydrazine functional groups provide multiple sites for further chemical modifications, making this compound particularly valuable for structure-activity relationship (SAR) studies in drug discovery programs.

In pharmacological research, (4-Bromo-3-methylphenyl)hydrazine has shown promise as a precursor for the development of MAO (monoamine oxidase) inhibitors. A recent preclinical study demonstrated that derivatives synthesized from this compound exhibited selective inhibition of MAO-B with IC50 values in the nanomolar range, suggesting potential applications in neurodegenerative disorders. The methyl substitution at the 3-position appears to contribute significantly to the compounds' blood-brain barrier permeability, as revealed by in vitro transport studies.

The mechanism of action of (4-Bromo-3-methylphenyl)hydrazine derivatives has been further elucidated through recent structural biology studies. X-ray crystallographic analysis of enzyme-inhibitor complexes has revealed that the bromine atom participates in key halogen bonding interactions with protein targets, while the hydrazine moiety forms crucial hydrogen bonds. These structural insights, published in a 2024 Nature Chemical Biology paper, provide a rational basis for the design of more potent and selective therapeutic agents.

From a safety and toxicological perspective, recent ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling of (4-Bromo-3-methylphenyl)hydrazine derivatives has yielded promising results. A comprehensive 2023 study in Chemical Research in Toxicology reported favorable metabolic stability and moderate plasma protein binding for several derivatives, though researchers noted the need for further optimization of pharmacokinetic properties. The bromine substitution was found to enhance metabolic stability compared to non-halogenated analogs.

Emerging applications in radiopharmaceutical development have also been reported. The bromine atom in (4-Bromo-3-methylphenyl)hydrazine provides a convenient site for radiohalogenation, enabling the synthesis of PET (Positron Emission Tomography) tracers. A recent proof-of-concept study successfully developed a fluorine-18 labeled analog that showed excellent tumor uptake in animal models, suggesting potential for cancer imaging applications.

In conclusion, (4-Bromo-3-methylphenyl)hydrazine (CAS: 90084-70-1) continues to be a valuable chemical scaffold in medicinal chemistry and chemical biology research. Recent advances have expanded our understanding of its synthetic utility, biological activities, and therapeutic potential. Future research directions likely include further optimization of its derivatives for improved drug-like properties and exploration of novel therapeutic indications.

• 6933-10-4(4-Bromo-3-methylaniline)
• 202925-03-9(4-Bromo-3-methylaniline hydrochloride)
• 156941-75-2((2-bromo-3-methylphenyl)hydrazine hydrochloride)
• 59557-90-3(4-Bromo-3,5-dimethylaniline)
• 90084-69-8((3-Bromo-4-methylphenyl)hydrazine)
• 884503-96-2(HYDRAZINE, (4-BROMO-3-METHYLPHENYL)-, HYDROCHLORIDE)
• 6311-56-4(Hydrazobenzene,3,5-dibromo-3',5'-dimethyl- (8CI))
• 90284-70-1((4-BROMO-3-METHYL-PHENYL)-HYDRAZINE)
• 459817-67-5((3-bromo-2-methylphenyl)hydrazine)
• 112626-91-2((3-Bromo-4-methylphenyl)hydrazine hydrochloride)